DBV Technologies (NASDAQ:DBVT) Share Price Crosses Above Fifty Day Moving Average - What's Next?

Key Points

• DBV Technologies shares recently surpassed their 50-day moving average, trading at $9.60, while their last traded price was $8.89.
• Wall Street analysts have given DBV Technologies a mixed outlook, with ratings ranging from "Strong Buy" to "Sell," and a consensus target price set at $14.75.
• The company reported a significant earnings miss with a loss of ($1.55) per share, well below analysts' expectations, amidst negative margins and modest revenue growth.

DBV Technologies S.A. (NASDAQ:DBVT - Get Free Report)'s stock price passed above its 50 day moving average during trading on Thursday . The stock has a 50 day moving average of $9.55 and traded as high as $9.60. DBV Technologies shares last traded at $8.89, with a volume of 59,258 shares traded.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on DBVT. Lifesci Capital raised shares of DBV Technologies to a "strong-buy" rating in a research report on Thursday, June 26th. Wall Street Zen downgraded shares of DBV Technologies from a "hold" rating to a "sell" rating in a research report on Friday, July 18th. The Goldman Sachs Group raised shares of DBV Technologies to a "sell" rating and set a $7.25 price objective for the company in a research report on Thursday, May 29th. Finally, JMP Securities reissued a "market outperform" rating and set a $21.00 price objective on shares of DBV Technologies in a research report on Thursday, June 26th. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, DBV Technologies currently has an average rating of "Moderate Buy" and a consensus target price of $14.75.

DBV Technologies Trading Down 5.0%

The business's 50 day moving average is $9.55 and its two-hundred day moving average is $8.82. The company has a market cap of $243.59 million, a PE ratio of -1.86 and a beta of -0.36.

DBV Technologies (NASDAQ:DBVT - Get Free Report) last released its earnings results on Tuesday, July 29th. The company reported ($1.55) earnings per share for the quarter, missing analysts' consensus estimates of ($0.21) by ($1.34). DBV Technologies had a negative net margin of 3,220.49% and a negative return on equity of 287.15%. The firm had revenue of $1.74 million for the quarter, compared to analysts' expectations of $0.64 million. As a group, equities research analysts predict that DBV Technologies S.A. will post -7.05 EPS for the current fiscal year.

Institutional Trading of DBV Technologies

Several hedge funds have recently bought and sold shares of DBVT. Nan Fung Trinity HK Ltd. purchased a new stake in DBV Technologies in the 2nd quarter worth $340,000. Octagon Capital Advisors LP purchased a new stake in DBV Technologies in the 2nd quarter worth $9,315,000. MPM Bioimpact LLC purchased a new stake in DBV Technologies in the 2nd quarter worth $9,649,000. Adage Capital Partners GP L.L.C. purchased a new stake in DBV Technologies in the 2nd quarter worth $9,659,000. Finally, Vivo Capital LLC purchased a new stake in DBV Technologies in the 2nd quarter worth $9,659,000. Hedge funds and other institutional investors own 71.74% of the company's stock.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.